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Over the past decade, a variety of benzothiazole derivatives have been reported with promising anticancer activity. 
Benzothiazole and its analogues are capable of acting on a number of molecular targets and thus exerting their anticancer 
activity. To further develop benzothiazole derivatives as anticancer agents, we attempted to design and synthesize a library 
of benzothiazole-triazole derivatives. The synthesized hybrid compounds have been selected by National Cancer Institute, 
USA for the in vitro activity evaluation against 60 human cancer cell lines in a one dose screening panel. Most of the 
synthesized compounds showed 60-80% growth rate against renal cancer cell line UO-31. 
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Cancer is an uncontrolled and rapid growth of 
abnormal cells1. It is the second leading cause of death 
after cardiovascular diseases with one in every six 
deaths worldwide. As estimated by International 
Agency for Research on Cancer, in the year 2018 
there were 18.1 million new cases around the world 
with 9.6 million cancer related deaths2. According to 
American Chemical Society by the year 2040, it is 
expected that 27.5 million new cancer cases and 16.3 
million cancer deaths can occur globally2,3. 
The successful treatment of cancer is a huge 
challenge due to early diagnosis difficulties, drug side 
effects, drug resistance and the malignancy of  
tumor metastasis. Thus, there is always a search for 
development of new antitumor agents4. Generally cancer 
therapy targeting a single biological molecule is being 
used4,5. However, better efficacy can be obtained by 
using agents which can modulate more than one target 
as compared to single target drugs5,6. Multiple targets 
can be modulated by the combination of various drugs 
having different mechanisms or by using ligands which 
comprise of two or more pharmacophores in a single 
biological molecule (hybrid drugs)6,7. Thus, hybrid drugs 
are designed with improved affinity and efficacy as 
compared to the parent drugs. 
Benzothiazoles are important class of heterocyclic 
compounds that have attracted great attention due  
to their antimicrobial8, antileshmanial9, antitumor10, 
anti-viral11, antimalarial12 and CNS depressant 
activities13. The promising biological activity profile and 
synthetic accessibility has led to development of new 
benzothiazoles as potential chemotherapeutics. In recent 
years, 2-arylbenzothiazoles and 2-aminobenzothiazoles 
have both emerged as important pharmacophores in 
the development of anticancer agents14. Various 
modified benzothiazole derivatives are even reported 
for inhibition of topoisomerase II15-18 (e.g. Figure 1a, 
1b), β-glucoronidase19 (e.g. Figure 1c), CYP1A1 of 
cytochrome P450 enzyme20 (e.g. Figure 1d) and 
tyrosine kinase histone deacetylase21 (e.g. Figure 1e) 
enzymes. While triazole is another important 
heterocyclic pharmacophore which notably has wide 
range of biological activities22,23. 
Using this hybrid approach and in-continuation of  
our work on the synthesis of biologically relevant 
molecules24-27, a series of benzothiazole-triazole hybrids 
were designed, synthesized and their anticancer activity 
was explored against a panel of different cancer cell 
lines (Figure 2). 
 
Result and Discussion 
 
Chemistry 
The synthesis of the designed set of hybrid compound 
was carried out as shown in Scheme I. Initially, 
commercially available 2-aminobenzothiazole (1) on 
reaction with chloroacetyl chloride in presence of K2CO3 




resulted in the formation of intermediate 2. The 
substitution of chloro group on intermediate 2 by azido 
(-N3) using sodium azide resulted in the formation of 
intermediate 2-azido-N-benzothiazol-2-yl-acetamide (3) 
which on click reaction with various substituted alkynes 
resulted in the formation of desired benzothiazole-
triazole hybrids 4a-j and 5a-n. 
 
In silico prediction of pharmacokinetic properties: 
In silico predictions of the pharmacokinetic 
properties of the designed hybrid molecules under 
study were explored using Qikprop v3.528. The 
important parameters with inclusion of their 
permissible range are mentioned in Table S2 and 
Table S3 (supporting file). It was observed that the 
designed set of hybrid compound follows the 
Lipinski's rule of five, which is a preliminary criterion 
to test drug-likeness for a compound. For this, any 
compound which is orally active should not violate 
more than 4 Lipinski Rules29. In our designed set of 
compounds (4a-j and 5a-n) as all hybrids successfully 
passed the Lipinski's rule, it indicates they have the 
potential to become orally active drug (in Table S2, 
supporting). In silico ADME predictions such as oral 
drug absorption (i.e. Percent Human Oral Absorption) 
was found in permissible range for all designed 
hybrids (in Table S3, supporting). The percentage 
values of most of the compound ranged between 80-
96, while few of them showed 100% oral absorption 
(4c, 4d, 5g, 5i and 5n). As reported earlier properties 
like molecular flexibilty affect oral bioavailability 
which is measured by the number of rotatable bonds 
(<15) in the compound30. The test set of compounds 
displayed rotatable bonds in the permissible range 
 
 




Figure 2 — Design of benzothiazole-triazole hybrids 
 




(i.e. < 15 rotatable bonds) (Table S3, supporting file). 
While other ADME parameters like Caco-2 cells 
permeability (QPPCaco) to measure intestinal drug 
absorption, QPlogKhsa for the prediction of human 
serum albumin binding both lied in the required range 
for all designed hybrids (Table S3, supporting file). 
Even the predicted values of brain/blood partition 
coefficient (QPlogBB), HERG-K+ channel inhibition 
(QPlogHERG) and the blood-brain barrier mimic 
MDCK cell permeability (QPPMDCK) all were found 
in permissible ranges (Table S3, supporting file). 
Overall, the molecules displayed good ADME properties. 
 
Anti-cancer Activity 
On the basis of pharmacokinetic profile, a series of 24 
benzothiazole-triazole derivatives were synthesised. 
Initially the structure of the designed compounds  
was uploaded on the US-NCI-DTP website (NCI 
Developmental Therapeutic Program) and the 24 
selected compounds were then screened against NCI 60 
cell line panel from nine different tissues for in vitro 
cytotoxicity. The details of the methodology for 
screening of compounds against NCI cell line are 
provided at http://dtp.nci.nih.gov/branches/ btb/ivclsp. 
html. The in-vitro screening done by NCI is a two-step 
process which begins with assessment of compound 
against NCI 60 cell line at 10 µM concentration. Only 
the compounds which show growth inhibition of more 
than 60% are selected for five dose studies. The one 
dose data of the selected 24 compounds at a single-dose 
concentration of 10 µM, and the percentages of growth 
rate over tested cell lines were determined. 
It can be seen from the data that most of the 
derivatives displayed weak growth inhibition against 
the mentioned cancer cell lines (Table S1, supporting 
file). Most of the compounds show 60-80% growth 
rate against renal cancer cell line UO-31 (Table I). 
Compounds 4a-4j with benzene ring via ether linkage 
(Table I) showed 65 to 74 percent growth. Compound 
4d with para ethyl group showed maximum inhibition 
amongst the series 4a-4j with 65% growth rate 
against UO-31 cell line. Replacement of ethyl group 
by methyl (4c) at para position resulted into decrease 
in inhibition. Amongst the CHO substituted derivatives 
compound 4j with meta CHO showed lesser growth 
of renal cancer cell line than the para (4a) and ortho 
(4e), respectively. Derivative with nitro group at para 
position (4g) showed maximum growth rate and 
hence least active. Amongst the series 5a-5n where 
various substituents are directly attached to triazole 
nucleus compound 5d with fluoro group showed least 
growth rate and maximum inhibition against renal 
cancer cell line UO-31. Amongst the alkyl substituted 
derivatives increase in chain length from n-propyl (5j) 
to n-butyl (5k) and then n-pentyl (5l) leads to decrease 
in inhibition. However, the n-hexyl substituent (5m) led 
to an increase in inhibition. The cyclopropyl (5f) 
derivative was least active amongst the series. 
 
Experimental Section 
Melting points (m.p.) were determined using the 
EZ-Melt automated melting point apparatus (Stanford 
Research Systems) and are uncorrected. Nuclear 
magnetic resonance (NMR) spectral data for proton 
 
 
Scheme I — Synthesis of benzothiazole-triazole hybrid 
 




NMR (1H NMR) at 400 MHz and carbon NMR  
(13C NMR) at 100 MHz were recorded using a  
Jeol ECX Spectrospin. All chemical shifts were 
referenced to tetramethylsilane (TMS) as internal 
standard reference. The shifts were reported in ppm 
(i.e. parts per million) with delta scale (δ). Infrared 
spectral (IR) data were determined using Perkin-
Elmer FT-IR spectrophotometer. Agilent Accurate-
Mass Q-TOF-MS mass spectrometer instrument was 
used to record mass of the compound. 
Commercial reagents and analytical grade solvents 
used for the reaction were directly used without 
purification. The chemicals and solvents used were 
purchased from Alfa Aesar, Sigma Aldrich, TCI 
Chemicals and Spectrochem. Reaction progress was 
monitored on thin layer chromatography sheets i.e. 
(TLC) of Merck Kiesel 60 F254 of 0.2 mm sheets. 
Spot of intermediates and final compounds monitored 
on TLC were visualized on UV-lamp, iodine stain  
or ninhydrin stain. The final compounds were pure 
(>90%) enough for biological studies as per their 
NMR data. 
 
Synthesis and Characterization of Compounds 
Synthesis of N-benzothiazol-2-yl-2-chloro-acetamide31, 
2: To a solution of 2-aminobenzothiazole (5g, 33.28 
mmol) in THF (50 mL) added K2CO3 (5g, 9.2 mmol) 
at 0°C followed by addition of chloroacetyl chloride 
(3.18 mL, 1.2 mmol). The reaction mixture was 
allowed to stir for 5 h at RT and the completion of 
reaction was monitored by TLC. After completion of 
reaction THF was removed followed by addition of 
water and the obtained white solid was filtered, dried 
and then used directly for the next step. Off-White 
solid. Yield: 81%. 1H NMR (DMSO-d6, 400 MHz): δ 
7.78 (dd, J = 4.4 Hz, 8.1 Hz, 2H), 7.41 (t, J = 8.11Hz, 
1H), 7.30 (t, J = 7.9 Hz, 1H), 4.25 (s, 2H); 13C NMR 
(DMSO-d6, 100 MHz): δ 164.79, 157.49, 147.71, 
131.95, 126.71, 124.67, 121.65, 121.12, 42.19. 
Synthesis of 2-azido-N-benzothiazol-2-yl-acetamide32,33, 
3: To a solution of compound 2 (4 g, 17.149 mmol) in 
DMF (20 mL) added NaN3 (2.23 g, 34.30 mmol) at 
40°C and reaction was kept for 3 h. Completion of 
reaction was monitored by TLC. Ice was added to 
above reaction mixture and obtained solid was filtered 
and washed with cold water and dried overnight. 
White solid. Yield: 74%. 1H NMR (DMSO-d6, 400 
MHz): δ 8.01 (d, J = 7.8 Hz, 1H), 7.77 (d, J = 7.9 Hz, 
1H), 7.46 (t, J = 7.3 Hz, 1H), 7.34 (t, J = 7.3 Hz, 1H), 
4.27 (s, 2H); 13C NMR (DMSO-d6, 100 MHz): δ 
168.34, 157.95, 148.90, 131.97, 126.77, 124.30, 
122.32, 121.17, 51.30. 
Synthesis of compound 4 or 5: To a solution of 
compound 3 (200 mg, 1eq) in THF:H2O (9:1) was 
added sodium ascorbate (0.02 eq) and CuSO4 (0.01 
eq) followed by alkyne (1.2 eq). After completion of 
the reaction as monitored by TLC, THF was 
evaporated using rotary-evaporator and the obtained 
product was extracted using ethyl acetate and purified 
by column chromatography. 
N-(Benzo[d]thiazol-2-yl)-2-(4-((4-formylphenoxy) 
methyl)-1H-1,2,3-triazol-1-yl)acetamide, 4a: Yield: 
76%. Solid. m.p.232-234°C. IR (CHCl3): 3422, 3298, 
3150, 2919, 2853, 2220, 1733, 1710, 1604, 1556, 
1508, 1458, 1442, 1418, 1382, 1318, 1295, 1272, 
1251, 1177, 1118, 1147, 1089, 1051, 1026, 863, 839, 
810, 780, 757, 724, 692, 663, 633, 561, 549, 482, 463 
cm−1; 1H NMR (DMSO-d6, 400 MHz): δ 9.88 (s, 1H), 
8.35 (s, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.89 (d, J = 8.7 
Hz, 2H), 7.78 (d, J = 8.2 Hz, 1H), 7.45 (t, J = 6.9 Hz, 
1H), 7.32 (t, J = 7.3 Hz, 1H), 7.27 (d, J = 8.7 Hz, 2H), 
Table I — Growth rate of compounds 4a-j and 5a-n against renal cancer cell line UO-31 
S.No. Entry Growth Percent S.No. Entry Growth Percent 
1 4a 67.66 13 5c 76.52 
2 4b 72.64 14 5d 60.63 
3 4c 70.56 15 5e 71.10 
4 4d 65.42 16 5f 78.40 
5 4e 73.14 17 5g 76.30 
6 4f 70.06 18 5h 66.75 
7 4g 74.23 19 5i 67.01 
8 4h 69.14 20 5j 65.95 
9 4i 73.35 21 5k 67.06 
10 4j 67.09 22 5l 70.22 
11 5a 72.11 23 5m 62.14 
12 5b 63.90 24 5n 62.89 
 




5.57 (s, 2H), 5.33 (s, 2H); 13C NMR (DMSO-d6,  
100 MHz): δ 192.28, 163.36, 142.55, 132.39, 130.38, 
127.31, 126.88, 124.66, 122.38, 121.24, 115.74, 
61.72, 52.10; ESI-HRMS: m/z Calcd for [(C19H15N5 
O3S)+H] +: 394.0974 (M+H)+. Obsd: 394.0957(M+H) +. 
N-(Benzo[d]thiazol-2-yl)-2-(4-(phenoxymethyl)-
1H-1,2,3-triazol-1-yl)acetamide, 4b: Yield: 64%; 
solid; m.p.255-257°C. IR (CHCl3): 3417, 2920, 2852, 
1694, 1612, 1495, 1462, 1442, 1382, 1272, 1239, 
1220, 1194, 1172, 1118, 1081, 1064, 1011, 980, 872, 
822, 749, 686, 669, 639, 564, 480, 461 cm−1; 1H NMR 
(DMSO-d6, 400 MHz): δ 8.30 (s, 1H), 7.99 (d, J = 7.8 
Hz, 1H), 7.78 (d, J = 8.2 Hz, 1H), 7.45 (t, J = 8.24 
Hz, 1H), 7.29-7.34 (m, 3H), 7.05 (d, J = 7.8 Hz, 2H), 
6.95 (t, J = 7.3 Hz, 1H), 5.56 (s, 2H), 5.17 (s, 2H); 
13C NMR (DMSO-d6, 100 MHz): δ 166.30, 158.56, 
157.88, 148.99, 143.22, 132.00, 130.07, 126.92, 
126.84, 124.39, 122.40, 121.38, 115.12, 61.31, 52.16. 
ESI-HRMS: m/z Calcd for [(C18H15N5O2S)+H]+: 
366.1025(M+H)+. Obsd: 366.1031 (M+H) +. 
N-(Benzo[d]thiazol-2-yl)-2-(4-((4-methylphenoxy) 
methyl)-1H-1,2,3-triazol-1-yl)acetamide, 4c: Yield: 
70%; solid; m.p.268-270°C. IR (CHCl3): 3408, 292, 
1698, 1611, 1576, 1511,1463, 1442, 1342, 1272, 
1241, 1179, 1063, 1041, 1016, 864, 808, 751, 723, 
506 cm−1; 1H NMR (DMSO-d6, 400 MHz): δ 12.86 
(brs, 1H), 8.25 (s, 1H), 7.96 (d, J = 7.7 Hz, 1H), 7.75 
(d, J = 8.1 Hz, 1H), 7.42 (t, J = 8.2 Hz, 1H), 7.29 (t, J 
= 7.1 Hz, 1H), 7.07 (d, J = 8.2 Hz, 2H), 6.91 (d, J = 
8.5 Hz, 2H), 5.53 (s, 2H), 5.10 (s, 2H), 2.20 (s, 3H); 
13C NMR (DMSO-d6, 100 MHz): δ 166.40, 158.01, 
156.51, 148.93, 143.31, 132.00, 130.38, 130.04, 
126.78, 124.37, 122.38, 121.26, 115.04, 61.52, 52.21, 
20.62; ESI-HRMS: m/z Calcd for [(C19H17 
N5O2S)+H]+: 380.1181(M+H)+, observed: 380.1163 
(M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-((4-ethylphenoxy) 
methyl)-1H-1,2,3-triazol-1-yl)acetamide, 4d: Yield: 
73%; solid; m.p.242-244°C. IR (CHCl3): 3429, 2922, 
1695, 1610, 1575, 1511, 1443, 1382, 1271, 1237, 
1064, 1013, 865, 824, 755, 471 cm−1; 1H NMR 
(DMSO-d6, 400 MHz): δ 8.29 (s, 1H), 7.99 (d, J = 7.3 
Hz, 1H), 7.78 (d, J = 8.2 Hz, 1H), 7.453 (t, J = 6.87, 
1H), 7.32 (t, J = 7.6 Hz, 1H), 7.13 (d, J = 8.7 Hz, 2H), 
6.96 (d, J = 8.7 Hz, 2H), 5.55 (s, 2H), 5.14 (s, 2H), 
2.53 (q, J = 7.8Hz, 2H), 1.14 (t, J = 7.8 Hz, 3H); 
13C NMR (DMSO-d6, 100 MHz): δ 166.36, 157.96, 
156.68, 149.01, 143.41, 136.59, 132.01, 129.20, 
126.80, 124.37, 122.38, 121.29, 115.03, 61.51,  
52.21, 27.84, 16.46. ESI-HRMS: m/z Calcd for 
[(C20H19N5O2S)+H]+: 394.1338 (M+H)+, observed: 
394.1349 (M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-((2-formylphenoxy) 
methyl)-1H-1,2,3-triazol-1-yl)acetamide, 4e: Yield: 
71%; solid; m.p.243-245°C. IR (CHCl3): 3233, 2921, 
1682, 1597, 1555, 1486, 1451, 1356, 1290, 1270, 
1240, 1219, 1190, 1045, 979, 848, 809, 756, 693, 491 
cm−1; 1H NMR (DMSO-d6, 400 MHz): δ 10.35 (s, 
1H), 8.39-8.40 (m, 1H), 7.97-7.99 (m, 1H), 7.76-7.78 
(m, 1H), 7.66-7.71 (m, 2H), 7.42-7.49 (m, 2H), 7.29-
7.34 (m, 1H), 7.09-7.13 (m, 1H), 5.56 (s, 2H), 5.39 (s, 
2H); 13C NMR (DMSO-d6, 100 MHz): δ 189.67, 
166.32, 160.95, 157.96, 148.99, 142.87, 137.06, 
131.99, 128.23, 127.00, 126.82, 125.01, 124.38, 
122.40, 121.70, 121.28, 114.74, 62.66, 52.25. ESI-
HRMS: m/z Calcd for [(C19H15 N5O3S)+H]+: 394.0974 
(M+H)+. Obsd: 394.0978 (M+H)+. 
2-(4-((4-Acetylphenoxy)methyl)-1H-1,2,3-triazol 
-1-yl)-N-(benzo[d]thiazol-2-yl)acetamide, 4f: Yield: 
56%; solid; m.p.258-260°C. IR (CHCl3): 3299, 3147, 
2919, 2849, 1716, 1609,1541, 1519, 1497, 1454, 
1412, 1342, 1295, 1262, 1224, 1167, 1141, 1110, 
1063, 1041, 1025, 979, 865, 839, 762, 748, 728, 684, 
655, 562, 531, 515, 493, 478, 431 cm−1; 1H NMR 
(DMSO-d6, 400 MHz): δ 8.34 (s, 1H), 7.99 (d, J = 6.9 
Hz, 1H), 7.94 (d, J = 8.7 Hz, 2H), 7.78 (d, J = 8.7 Hz, 
1H), 7.45 (s, 1H), 7.33 (d, J = 6.9 Hz, 1H), 7.17 (d, J 
= 8.7Hz, 2H), 5.57 (s, 2H), 5.30 (s, 2H), 2.52 (s, 3H); 
13C NMR (DMSO-d6, 100 MHz): δ 196.89, 166.39, 
162.41, 158.01, 148.92, 142.68, 131.97, 131.02, 
130.66, 127.15, 126.82, 124.38, 122.39, 121.26, 
115.06, 61.77, 52.25, 26.96. ESI-HRMS: m/z Calcd 
for [(C20H17N5O3S)+H]+ : 408.1130 (M+H)+,observed: 
408.1119(M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-((4-nitrophenoxy) 
methyl)-1H-1,2,3-triazol-1-yl)acetamide 4g: Yield: 
71%; solid; m.p.256-258°C. IR (CHCl3): 3220, 3147, 
2923, 2853, 1735, 1705, 1658, 1600, 1559, 1511, 
1460, 1442, 1421, 1380, 1358, 1318, 1293, 1277, 
1250, 1182, 1148, 1080, 1048, 1024, 1004, 963, 864, 
832, 806, 747, 727, 671, 632, 579, 540, 499, 485, 408 
cm−1; 1H NMR (DMSO-d6, 400 MHz): δ 8.36 (s, 1H), 
8.23 (d, J = 9.2 Hz, 2H), 7.98 (d, J = 7.8 Hz, 1H), 
7.78 (d, J = 7.8 Hz, 1H), 7.45 (t, J = 7.8 Hz, 1H), 7.31 
(m, 3H), 5.57 (s, 2H), 5.37 (s, 2H); 13C NMR 
(DMSO-d6, 100 MHz): δ 166.36, 163.84, 158.02, 
148.84, 142.24, 141.58, 131.96, 127.35, 126.83, 
126.4, 124.41, 122.37, 121.23, 115.85, 62.36, 52.26; 
ESI-HRMS: m/z Calcd for [(C18H14N6O4S)+H]+: 
411.0875 (M+H) +. Obsd: 411.0887 (M+H)+. 





methyl)-1H-1,2,3-triazol-1-yl)acetamide, 4h: Yield: 
71%; solid; m.p.257-259°C. IR (CHCl3): 3433, 2922, 
1696, 1610, 1574, 1488, 1463, 1442, 1411, 1343, 
1273, 1235, 1174, 1063, 1041, 1010, 978, 863, 815, 
754, 725, 640, 616, 500 cm−1; 1H NMR (DMSO-d6, 
400 MHz): δ 8.30 (s, 1H), 7.99 (d, J = 7.8 Hz, 1H), 
7.78 (d, J = 7.8 Hz, 1H), 7.43-7.48 (m, 3H), 7.32 (t, J 
= 7.6 Hz, 1H), 7.04 (d, J = 8.7 Hz, 2H), 5.55 (s, 2H), 
5.18 (s, 2H); 13C NMR (DMSO-d6, 100 MHz): δ 
166.40, 158.15, 148.95, 142.87, 132.69, 131.99, 
127.00, 126.80, 124.35, 122.37, 121.23, 117.56, 
112.82, 62.00, 52.41. ESI-HRMS: m/z Calcd for 
[(C18H14BrN5O2S)+H]+: 444.0130 (M+H)+. Obsd: 
444.0119 (M+H)+, 446.0099 (MH+2)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-((4-cyanophenoxy) 
methyl)-1H-1,2,3-triazol-1-yl)acetamide, 4i: Yield: 
78%; solid; m.p.267-269°C. IR (CHCl3): 3416, 2921, 
2853, 1695, 1606, 1459, 1441, 1382, 1304, 1273, 
1243, 1163, 1064, 1012, 866, 824, 755, 726, 637, 609, 
481 cm−1; 1H NMR (DMSO-d6, 400 MHz): δ 8.34 (s, 
1H), 7.99 (d, J = 7.8 Hz, 1H), 7.79 (t, J = 8.0 Hz, 3H), 
7.45 (t, J = 7.8 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 7.25 
(d, J = 8.7 Hz, 2H), 5.57 (s, 2H), 5.31 (s, 2H); 
13C NMR (DMSO-d6, 100 MHz): δ 166.37, 162.03, 
158.02, 148.89, 142.42, 134.74, 131.98, 127.25, 
126.81, 124.37, 122.37, 121.24, 119.64, 116.34, 
103.71, 61.93, 52.27; ESI-HRMS: m/z Calcd for 
[(C19H14N6O2S)+H]+: 391.0977 (M+H)+. Obsd: 
391.0980 (M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-((3-formylphenoxy) 
methyl)-1H-1,2,3-triazol-1-yl)acetamide, 4j: Yield: 
73%; solid; m.p.222-224°C. IR (CHCl3): 3430, 2921, 
2870, 1699, 1608, 1533, 1480, 1444, 1383, 1364, 
1287, 1270, 1062, 839, 751,725, 677, 562 cm−1; 
1H NMR (DMSO-d6, 400 MHz): δ 9.99 (s, 1H), 8.34 
(s, 1H), 7.98-8.00 (m, 1H), 7.77-7.79 (m, 1H), 7.54-
7.58 (m, 3H), 7.40-7.45 (m, 2H), 7.32-7.33 (m, 1H), 
5.58 (s, 2H), 5.29 (s, 2H); 13C NMR (DMSO-d6, 100 
MHz): δ 193.43, 166.41, 159.12, 158.07, 148.88, 
142.86, 138.20, 131.99, 130.96, 127.05, 126.80, 
124.36, 123.19, 122.37, 122.09, 121.24, 114.71, 
61.81, 52.26; ESI-HRMS: m/z Calcd for [(C19H15 
N5O3S)+H]+: 394.0974 (M+H)+. Obsd: 394.0981 
(M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-(hydroxymethyl)-
1H-1,2,3-triazol-1-yl)acetamide, 5a: Yield: 69%; 
solid; m.p.222-224°C. IR(CHCl3): 3284, 3151, 2848, 
1687, 1608, 1571, 1490, 1440, 1298, 1271, 1228, 
1197, 1141, 1020, 968, 875, 813, 754, 729, 688, 572 
cm−1; 1H NMR (DMSO-d6, 400 MHz): δ 8.03 (s, 1H), 
7.98 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 7.8 Hz, 1H), 
7.45 (t, J = 7.8 Hz, 1H), 7.31 (t, J = 7.8 Hz, 1H), 5.51 
(s, 2H), 5.24 (brs, 1H), 4.55 (d, J = 5.0 Hz, 2H); 
13C NMR (DMSO-d6,100 MHz): δ 166.47, 158.02, 
148.96, 148.53, 131.97, 126.82, 125.03, 124.70, 
124.36, 122.38, 121.24, 55.54, 52.06; ESI-HRMS:  
for [C12H11N5O2S)+H]+: 290.0712 (M+H)+. Obsd: 
290.0709(M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-phenyl-1H-1,2,3-
triazol-1-yl)acetamide, 5b32: Yield: 66%; solid; 
m.p.248-250°C. IR (CHCl3): 3432, 2923, 2854, 1721, 
1645, 1601, 1541, 1463, 1441, 1381, 1349, 1294, 
1272, 1233, 1177, 1131, 1078, 1048, 1020, 971, 883, 
808, 770, 754, 732, 710, 693, 609, 557, 507, 494, 477, 
456, 429 cm−1; 1H NMR (DMSO-d6, 400 MHz): δ 
8.63 (s, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.87 (d, J = 7.6 
Hz, 2H), 7.78 (d, J = 7.8 Hz, 1H), 7.43-7.48 (m, 3H), 
7.29-7.36 (m, 2H), 5.59 (s, 2H); 13C NMR (DMSO-d6, 
100 MHz) δ = 166.43, 158.09, 148.86, 146.90, 
131.99, 131.14, 129.48, 128.47, 126.81, 125.72, 
124.36, 123.67, 122.38, 121.23, 52.38; ESI-HRMS: 
m/z Calcd for [(C17H13N5OS)+H]+: 336.0919 (M+H)+. 
Obsd: 336.0899 (M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-(1-hydroxycyclohexyl) 
-1H-1,2,3-triazol-1-yl)acetamide, 5c: Yield: 73%; 
solid; m.p.206-208°C. IR (CHCl3): 3262, 3067, 2931, 
2853, 1698, 1604, 1566, 1443, 1409, 1382, 1347, 
1294, 1270, 1232, 1180, 1159, 1129, 1071, 1058, 
1035, 1017, 980, 895, 879, 848, 833, 808, 795, 755, 
722, 695, 661, 567, 522 486, 432, 408 cm−1; 1H NMR 
(DMSO-d6, 400 MHz): δ = 8.00 (d, J = 7.8 Hz, 1H), 
7.97 (s, 1H), 7.79 (d, J = 7.8 Hz, 1H), 7.46 (t, J = 7.3 
Hz, 1H), 7.33 (t, J = 7.3 Hz, 1H), 5.50 (s, 2H), 4.95  
(s, 1H), 1.89 (t, J = 10.1 Hz, 2H), 1.67-1.74 (m, 4H), 
1.52-1.57 (m, 1H), 1.43-1.46 (m, 2H), 1.23-1.34 (m, 
1H); 13C NMR (DMSO-d6, 100 MHz): δ 166.44, 
157.94, 156.40, 149.02, 132.01, 126.80, 124.350, 
123.25, 122.37, 121.30, 68.55, 52.03, 38.36, 25.78, 
22.17; ESI-HRMS: m/z Calcd for [(C17H19N5 
O2S)+H]+: 358.1338 (M+H) +. Obsd: 358.1332 (M+H) +. 
N-(Benzo[d]thiazol-2-yl)-2-(4-(4-fluorophenyl)-
1H-1,2,3-triazol-1-yl)acetamide, 5d33: Yield: 72%; 
solid; m.p.255-257°C. IR(CHCl3): 3205, 3073, 2993, 
1711, 1598, 1557, 1496, 1456, 1443, 1427, 1376, 
1349, 1278, 1264, 1227, 1181, 1156, 1095, 1074, 
1033, 985, 872, 838, 817, 795, 758, 725, 679, 656, 
601, 570, 539, 517, 478, 432 cm−1; 1H NMR (DMSO-
d6, 400 MHz): δ 8.63 (s, 1H), 7.99 (d, J = 7.8 Hz, 1H), 
7.90-7.94 (m, 2H), 7.7 (d, J = 8.2 Hz, 1H), 7.45 (t, J = 




7.8 Hz, 1H), 7.28-7.34 (m, 3H), 5.60 (s, 2H); 
13C NMR (DMSO-d6,100 MHz): δ 166.36, 163.56, 
161.13, 148.79, 146.05, 131.96, 127.80, 127.72, 
126.84, 124.40, 123.58, 122.41, 121.33, 116.54, 
116.33, 52.11; ESI-HRMS: m/z Calcd for 
[(C17H12FN5OS)+H]+: 354.0825 (M+H) +. 
Obsd:354.0817(M+H) +. 
N-(Benzo[d]thiazol-2-yl)-2-(4-(4-methoxyphenyl)- 
1H-1,2,3-triazol-1-yl)acetamide, 5e33: Yield: 76%; 
m.p.242-244°C. IR (CHCl3): 3431, 3084, 2922, 1725, 
1596, 1556, 1542, 1457, 1442, 1411, 1373, 1273, 
1249, 1175, 1085, 1050, 1025, 973, 886, 832, 816, 
795, 754, 607, 562, 530, 478 cm−1; 1H NMR (DMSO-
d6, 400 MHz): δ 8.53 (s, 1H), 8.00 (d, J = 7.8 Hz, 1H), 
7.81 (d, J = 8.7 Hz, 3H), 7.46 (t, J = 7.3Hz, 1H),  
7.33 (t, J = 7.3 Hz, 1H), 7.04 (d, J = 8.7 Hz, 2H), 5.58 
(s, 2H), 3.80 (s, 3H); 13C NMR (DMSO-d6, 100 
MHz): δ 166.48, 159.60, 158.07, 148.91, 146.89, 
132.01, 127.11, 126.81, 124.38, 123.72, 122.69, 122.37, 
121.24, 114.88, 55.65, 52.33; ESI-HRMS: Calcd for 
[(C18H15 N5O2S) +H]+: 366.1025(M+H)+. Obsd: 
366.1011 (M+H) +. 
N-(Benzo[d]thiazol-2-yl)-2-(4-cyclopropyl-1H-
1,2,3-triazol-1-yl)acetamide, 5f: Yield: 68%; solid; 
m.p.230-232°C. IR (CHCl3): 3134, 3084, 2916, 1713, 
1604, 1558, 1481, 1443, 1411, 1375, 1334, 1311, 
1292, 1270, 1219, 1186, 1141, 1063, 1017, 979, 901, 
871, 810, 748, 717, 671, 614, 570, 540, 515, 431 
cm−1; 1H NMR (DMSO-d6, 400 MHz): δ 7.98 (d, J = 
7.8 Hz, 1H), 7.89 (s, 1H), 7.77 (d, J = 8.2 Hz, 1H), 
7.4 (t, J = 7.8 Hz, 1H), 7.31 (t, J = 6.9 Hz, 1H), 5.46 
(s, 2H), 1.93-1.99 (m, 1H), 0.88-0.92 (m, 2H), 0.71-
0.75 (m, 2H); 13C NMR (DMSO-d6, 100 MHz): δ 
166.47, 158.02, 149.49, 148.79, 131.91, 126.84, 
124.40, 123.09, 122.34, 121.21, 52.02, 8.18, 6.98; 
ESI-HRMS: m/z Calcd for [(C14H13N5OS)+H]+: 
300.0919 (M+H)+, Observed Mass: 300.0902(M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-cyclohexyl-1H-
1,2,3-triazol-1-yl)acetamide, 5g: Yield: 69%; solid; 
m.p.222-224°C. IR (CHCl3): 3627, 3408, 2922, 1721, 
1602, 1559, 1536, 1498, 1442, 1364, 1272, 1229, 
1180, 1156, 1081, 1049, 975, 830, 755, 601, 477 
cm−1; 1H NMR (DMSO-d6, 400 MHz): δ 7.98 (d, J = 
7.8, 1H), 7.89 (s, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.44 
(t, J = 7.8 Hz, 1H), 7.31 (t, J = 8.2 Hz, 1H), 5.46 (s, 
2H), 2.66-2.70 (m, 1H), 1.95-1.97 (m, 2H), 1.65-1.74 
(m, 2H), 1.31-1.43 (m, 4H), 1.22-1.24 (m, 2H); 
13C NMR (DMSO-d6, 100 MHz): δ 166.52, 158.01, 
152.62, 148.90, 131.98, 126.79, 124.34, 122.81, 
122.35, 121.24, 52.03, 35.12, 33.06, 26.14; ESI-
HRMS: m/z Calcd for [(C17H19N5OS)+H]+: 342.1389 
(M+H)+. Obsd: 342.1394(M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-(4-cyanophenyl)-
1H-1,2,3-triazol-1-yl)acetamide, 5h33: Yield: 50%; 
solid; m.p.246-248°C. IR (CHCl3): 3369, 3142, 2920, 
2852, 2220, 1683, 1647, 1602, 1564, 1490, 1448, 
1392, 1352, 1298, 1269, 1184, 1070, 1037, 1014, 972, 
875, 844, 800, 771, 678, 623, 576, 547 cm−1; 1H NMR 
(DMSO-d6, 400 MHz): δ 8.84 (s, 1H), 8.08 (d, J = 8.2 
Hz, 2H), 7.98 (d, J = 7.8Hz, 1H), 7.93 (d, J = 8.2 Hz, 
2H), 7.78 (d, J = 8.2 Hz, 1H), 7.45 (t, J = 7.3 Hz, 1H), 
7.32 (t, J = 7.3 Hz, 1H), 5.64 (s, 2H); 13C NMR 
(DMSO-d6, 100 MHz): δ 166.25, 158.05, 148.89, 
145.34, 135.57, 133.60, 131.97, 126.84, 125.39, 
124.41, 122.42, 121.27, 119.36, 110.74, 52.50; ESI-
HRMS: m/z Calcd for [(C18H12N6OS)+H]+: 361.0872 
(M+H)+. Obsd:361.0877 (M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-(p-tolyl)-1H-1,2,3-
triazol-1-yl)acetamide, 5i: Yield: 73%; solid; 
m.p.263-265°C. IR (CHCl3): 3626, 3403, 3154, 3047, 
2922, 2853, 1852, 1806, 1729, 1652, 1597, 1548, 
1497, 1445, 1413, 1381, 1342, 1294, 1271, 1234, 
1209, 1173, 1132, 1071, 1048, 987, 971, 879, 804, 
766, 648, 556, 539, 489, 471, 408 cm−1; 1H NMR 
(DMSO-d6, 400 MHz): δ 8.57 (s, 1H), 7.99 (d, J = 7.8 
Hz, 1H), 7.75-7.79 (m, 3H), 7.45 (t, J = 7.3 Hz, 1H), 
7.32 (t, J = 7.3Hz, 1H), 7.27 (d, J = 7.8 Hz, 2H), 5.58 
(s, 2H), 2.33 (s, 3H); 13C NMR (DMSO-d6, 100 
MHz): δ 166.20, 157.83, 148.65 146.79, 137.66, 
131.74, 129.85, 128.07, 126.64, 125.45, 124.21, 
123.03, 122.15, 121.03, 52.08, 21.15; ESI-HRMS: 
m/z Calcd for [(C18H15N5OS)+H]+: 350.1076 (M+H)+. 
Obsd: 350.1071(M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-propyl-1H-1,2,3-
triazol-1-yl)acetamide, 5j: Yield: 51%; solid; 
m.p.208-210°C. IR (CHCl3): 3435, 2922, 1681, 1605, 
1568, 1442, 1427, 1381, 1266, 1219, 1143, 1055, 978, 
872, 795, 747, 725, 663, 570, 481 cm−1; 1H NMR 
(DMSO-d6, 400 MHz): δ 7.88 (d, J = 7.8 Hz, 1H), 
7.80 (s, 1H), 7.67 (d, J = 8.2 Hz, 1H), 7.34 (d, J = 7.8 
Hz, 1H), 7.21 (d, J=7.8 Hz, 1H), 5.36 (s, 2H), 2.51 (t, 
J = 7.8 Hz, 2H), 1.47-1.56 (m, 2H), 0.81 (t, J =7.6 Hz, 
3H); 13C NMR (DMSO-d6, 100 MHz): δ 166.52, 
158.00, 149.00, 147.24, 131.97, 126.80, 124.34, 
124.15, 122.37, 121.24, 52.00, 27.54, 22.80, 14.16; 
ESI-HRMS: m/z Calcd for [(C14H15N5OS)+H]+: 
302.1076 (M+H)+. Obsd: 302.1084(M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-butyl-1H-1,2,3-
triazol-1-yl)acetamide, 5k: Yield: 54%; solid; 
m.p.199-201°C. IR (CHCl3): 3409, 3133, 3005, 2953, 




2925, 2854, 1689, 1606, 1567, 1459, 1442, 1427, 
1381, 1287, 1267, 1199, 1142, 1086, 1055, 1034, 981, 
956, 874, 831, 817, 749, 725, 689, 663, 618, 569, 480, 
429 cm−1; 1H NMR (DMSO-d6, 400 MHz): δ 7.98 (d, 
J = 7.8 Hz, 1H), 7.90 (s, 1H), 7.78 (d, J = 7.8 Hz, 
1H), 7.45 (d, J = 7.3Hz, 1H), 7.31 (d, J = 7.3Hz, 1H), 
5.47 (s, 2H), 2.64 (d, J = 7.8 Hz, 2H), 1.55-1.62 (m, 
2H), 1.28-1.38 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H); 
13C NMR (DMSO-d6, 100 MHz): δ 166.48, 157.93, 
148.97, 147.40, 131.97, 126.82, 124.36, 124.11, 
122.38, 121.28, 51.97, 31.64, 25.14, 22.21, 14.25; 
ESI-HRMS: m/z Calcd for [(C15H17N5OS)+H]+: 
316.1232 (M+H)+. Obsd: 316.1238(M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-pentyl-1H-1,2,3-
triazol-1-yl)acetamide, 5l: Yield: 48%; solid; 
m.p.203-205°C. IR (CHCl3): 3182, 3147, 3066, 2991, 
2924, 2860, 1680, 1602, 1558, 1463, 1435, 1361, 
1292, 1261, 1193, 1143, 1087, 1053, 1022, 974, 927, 
871, 812, 788, 750, 723, 661, 569, 538, 514 cm−1; 
1H NMR (DMSO-d6, 400 MHz): δ 7.96 (d, J = 7.8 
Hz, 1H), 7.88 (s, 1H), 7.75 (d, J= 8.2 Hz, 1H), 7.42 (t, 
J = 7.8 Hz, 1H), 7.29 (t, J = 7.8 Hz, 1H), 5.45 (s, 2H), 
2.60 (t, J = 7.8 Hz, 2H), 1.54-1.61 (m, 2H), 1.25-1.30 
(m, 4H), 0.84 (t, J = 6.9 Hz, 3H); ESI-HRMS: m/z 
Calcd for [(C16H19N5OS)+H]+: 330.1389 (M+H)+. 
Obsd: 330.1372 (M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-hexyl-1H-1,2,3-
triazol-1-yl)acetamide, 5m: Yield: 50%; solid; 
m.p.204-206°C. IR (CHCl3): 3432, 3126, 3062, 2923, 
2853, 1726, 1595, 1556, 1536, 1457, 1442 1405, 
1363, 1273, 1226, 1211, 1172, 1057, 977, 886, 824, 
754, 729, 562, 478 cm−1; 1H NMR (DMSO-d6, 400 
MHz): δ 7.86 (d, J = 7.8 Hz, 1H), 7.78 (s, 1H), 7.65 
(d, J = 7.8 Hz, 1H), 7.32 (t, J= 8.2 Hz, 1H), 7.19  
(t, J = 7.8 Hz, 1H), 5.35 (s, 2H), 2.51 (t, J = 7.8 Hz, 
2H), 1.44-1.49 (m, 2H), 1.09-1.15 (m, 6H), 0.73  
(s, 3H); 13C NMR (DMSO-d6, 100 MHz)  
δ =166.16, 157.67, 148.50, 147.15, 131.58, 126.50, 
124.06, 123.79, 122.02, 120.88, 51.64, 31.19, 29.08, 
28.42, 25.10, 22.21, 14.10; ESI-HRMS: m/z Calcd for 
[(C17H21N5OS)+H]+: 344.1545 (M+H)+. Obsd: 
344.1549(M+H)+. 
N-(Benzo[d]thiazol-2-yl)-2-(4-(4-propylphenyl)-
1H-1,2,3-triazol-1-yl)acetamide, 5n: Yield: 62%; 
solid; m.p.249-251°C. IR (CHCl3): 3912, 3883, 3775, 
3719, 3659, 3430, 2923, 2854, 1853, 1721, 1597, 
1557, 1535, 1443, 1381, 1272, 1233, 1176, 1079, 
1049, 977, 884, 813, 748, 725, 561, 471, 433, 414 
cm−1; 1H NMR (DMSO-d6, 400 MHz): δ 8.47 (s, 1H), 
7.89 (d, J = 7.79 Hz, 1H), 7.67-7.69 (m, 3H), 7.35  
(t, J=7.8 Hz, 1H), 7.22 (t, J=7.3 Hz, 1H), 7.17 (d, J = 
7.8 Hz, 2H), 5.49 (s, 2H), 2.47 (t, J = 7.3 Hz, 2H), 
1.46-1.54 (m, 2H), 0.80 (t, J=7.3 Hz, 3H); 13C NMR 
(DMSO-d6, 100 MHz): δ 166.45, 158.11, 148.93, 
146.98, 142.48, 132.01, 129.43, 128.66, 126.81, 
125.67, 124.36, 123.27, 122.40, 121.24, 52.34,  
37.52, 24.51, 14.15; ESI-HRMS: m/z Calcd for 




Herein we report the design, synthesis and one  
dose anticancer activity (selected by NCI) of 24 
benzothiazole-triazole hybrids. All of the synthesized 
compounds showed growth percent in the range of  
60-80% for UO-31 renal cancer cell line (data obtained 
from NCI). As the designed series even follow in silco 
pharmacokinetic parameters, hence these compounds 
can result in design and development of potent leads. 
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